Freedom Broker initiated coverage of Sanara MedTech (SMTI) with a Buy rating and $35 price target Sanara develops and commercializing products for surgical wound and soft tissue management, the analyst tells investors in a research note. The firm sees the company’s growth coming from continued share gains in soft tissue products, broader access, and portfolio expansion across adjacent surgical and biologic offerings.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SMTI:
Disclaimer & DisclosureReport an Issue
